Literature DB >> 18070970

Intracellular efavirenz levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected individuals.

Rie Tanaka1, Hideji Hanabusa, Ei Kinai, Naoki Hasegawa, Masayoshi Negishi, Shingo Kato.   

Abstract

We describe a novel method for isolating plasma-free peripheral blood mononuclear cells retaining intracellular efavirenz. Quantification of efavirenz in 13 human immunodeficiency virus-infected patients by liquid chromatography-tandem mass spectrometry showed a higher correlation of intracellular levels with unbound plasma levels (accumulation ratio, 1,190) than with total plasma levels.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18070970      PMCID： PMC2224777          DOI： 10.1128/AAC.01613-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

Review 1.  The intracellular pharmacology of antiretroviral protease inhibitors.

Authors:  J Ford; S H Khoo; D J Back
Journal:  J Antimicrob Chemother       Date:  2004-11-10       Impact factor: 5.790

2.  Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry.

Authors:  S Colombo; A Beguin; A Telenti; J Biollaz; T Buclin; B Rochat; L A Decosterd
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2005-05-25       Impact factor: 3.205

3.  Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals.

Authors:  Lisa M Almond; Patrick G Hoggard; Damitha Edirisinghe; Saye H Khoo; David J Back
Journal:  J Antimicrob Chemother       Date:  2005-09-01       Impact factor: 5.790

4.  Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport.

Authors:  K Jones; P G Hoggard; S D Sales; S Khoo; R Davey; D J Back
Journal:  AIDS       Date:  2001-04-13       Impact factor: 4.177

5.  Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.

Authors:  Margalida Rotger; Sara Colombo; Hansjakob Furrer; Gabriela Bleiber; Thierry Buclin; Belle L Lee; Olivia Keiser; Jérôme Biollaz; Laurent Décosterd; Amalio Telenti
Journal:  Pharmacogenet Genomics       Date:  2005-01       Impact factor: 2.089

6.  Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Authors:  C Marzolini; A Telenti; L A Decosterd; G Greub; J Biollaz; T Buclin
Journal:  AIDS       Date:  2001-01-05       Impact factor: 4.177

7.  P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?

Authors:  K Jones; P G Bray; S H Khoo; R A Davey; E R Meaden; S A Ward; D J Back
Journal:  AIDS       Date:  2001-07-27       Impact factor: 4.177

8.  Intracellular accumulation of human immunodeficiency virus protease inhibitors.

Authors:  Saye H Khoo; Patrick G Hoggard; Ian Williams; E Rhiannon Meaden; Philippa Newton; Edmund G Wilkins; Alan Smith; John F Tjia; Judy Lloyd; Kevin Jones; Nick Beeching; Peter Carey; Barry Peters; David J Back
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

9.  Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication.

Authors:  W Y Gao; A Cara; R C Gallo; F Lori
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

10.  Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.

Authors:  Chantal Csajka; Catia Marzolini; Karin Fattinger; Laurent A Décosterd; Jacques Fellay; Amalio Telenti; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacol Ther       Date:  2003-01       Impact factor: 6.875
  10 in total
  6 in total

1.  Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz.

Authors:  Dhwanil A Dalwadi; Seongcheol Kim; Shahnawaz M Amdani; Zhenglan Chen; Ren-Qi Huang; John A Schetz
Journal:  Pharmacol Res       Date:  2016-05-06       Impact factor: 7.658

2.  Hypromellose acetate succinate based amorphous solid dispersions via hot melt extrusion: Effect of drug physicochemical properties.

Authors:  Sandeep Sarabu; Venkata Raman Kallakunta; Suresh Bandari; Amol Batra; Vivian Bi; Thomas Durig; Feng Zhang; Michael A Repka
Journal:  Carbohydr Polym       Date:  2020-01-10       Impact factor: 9.381

3.  A rapid spin through oil results in higher cell-associated concentrations of antiretrovirals compared with conventional cell washing.

Authors:  Theodore J Cory; Lee C Winchester; Brian L Robbins; Courtney V Fletcher
Journal:  Bioanalysis       Date:  2015       Impact factor: 2.681

4.  No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.

Authors:  Jürgen Burhenne; Anne-Kathrin Matthée; Ivana Pasáková; Claudia Röder; Tilman Heinrich; Walter Emil Haefeli; Gerd Mikus; Johanna Weiss
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

5.  Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.

Authors:  Abhijit A Date; Annemarie Shibata; Michael Goede; Bridget Sanford; Krista La Bruzzo; Michel Belshan; Christopher J Destache
Journal:  Antiviral Res       Date:  2012-10-03       Impact factor: 5.970

6.  Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6.

Authors:  A Ke; Z Barter; K Rowland-Yeo; L Almond
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-07-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.